Skip to main content
The Lotus Endometriosis Institute Logo
A beautiful landscape of lotus flowers

Relugolix for Endometriosis Pain: What a 2025 Meta-Analysis Says About Relief, Quality of Life, and Side Effects

What the latest evidence says about pain relief, quality of life (EHP-30), side effects, add-back therapy, and how relugolix compares to leuprorelin.

By Dr Steven Vasilev
A Black woman in a modern home office reviews a laptop showing a clean forest plot comparing relugolix and leuprorelin with an EHP-30 chart, a note about add-back therapy, and a pill organizer on the desk.

Living with endometriosis can mean dealing with persistent pelvic pain, painful periods, and the emotional toll of symptoms that affect work, relationships, and daily routines. Newer oral medications—like relugolix—are being studied and used to help reduce endometriosis-associated pain and improve quality of life.


This post summarizes patient-relevant findings from a 2025 systematic review and meta-analysis of randomized controlled trials (RCTs)published in Frontiers in Endocrinology that evaluated relugolix using the Endometriosis Health Profile-30 (EHP-30), a common endometriosis quality-of-life questionnaire.


What is endometriosis—and why can it hurt so much?


Endometriosis is often described as a chronic condition where tissue similar to the lining of the uterus is found outside the uterus. Many people experience pain that can be intense and life-disrupting. This meta-analysis focused on endometriosis-associated pain and how treatment affected pain and quality of life as captured by EHP-30 scores.


How does relugolix work?


Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist. In plain language: it works by reducing hormonal signals that contribute to endometriosis-related pain.


The review also discusses a key practical difference from some older GnRH-based treatments (like GnRH agonists such as leuprorelin): relugolix may provide comparable benefit without an initial “flare-up” of symptoms that can happen when starting a GnRH agonist. (The paper emphasizes non-inferiority vs leuprorelin and notes the lack of a flare-up as a potential advantage.)


Does relugolix reduce endometriosis pain? What the evidence shows


Across the included RCTs, relugolix was associated with meaningful improvements in EHP-30 pain-related outcomes—especially compared with placebo (no active treatment).


Key findings (vs placebo):

  • Improved EHP-30 Pain domain scores: mean difference (MD) 6.77(95% CI 3.15 to 10.39, p=0.0002)
  • Higher likelihood of being a “responder” on the EHP-30 Pain domain: odds ratio (OR) 3.245(95% CI 2.496 to 4.219, p < 0.0001)


What this means for patients: in these studies, people taking relugolix were more likely to report meaningful pain improvement than those taking placebo.


Beyond pain: quality-of-life improvements (EHP-30 domains)


Endometriosis isn’t only about pain levels—it can affect mood, relationships, and self-confidence. In this meta-analysis, relugolix also improved several quality-of-life areas compared with placebo:

  • Emotional well-being: MD 5.71(95% CI 1.87 to 9.55, p=0.0036)
  • Social support: MD 6.40(95% CI 0.88 to 11.93, p=0.0231)
  • Self-image: MD 6.00(95% CI 1.03 to 10.96, p=0.0179)


If you’ve felt that endometriosis affects your mental health or sense of self, these findings are important: the research suggests relugolix may help improve how you feel and function, not just pain scores.


How does relugolix compare with leuprorelin (an older GnRH treatment)?


Some trials compared relugolix with leuprorelin (a GnRH agonist). The review concludes that:

  • Relugolix is generally non-inferior (meaning “not worse”) compared with leuprorelin.
  • It was not statistically superior (not clearly better) for overall efficacy or quality-of-life impact.
  • In results summarized by the authors, relugolix showed a numerically smaller improvement than leuprorelin in at least one analysis (reported as MD -3.79, 95% CI -6.27 to -1.31), and the discussion notes the confidence intervals did not show clear superiority.


Patient takeaway: Relugolix may be an alternative option with similar overall benefit, and it may avoid the initial symptom flare associated with starting a GnRH agonist—an issue some patients find difficult.


Ready to Tackle Endometriosis Pain?

Our specialists are here to help you understand your condition and explore your treatment options.

Schedule Your Consult

Side effects and “add-back” therapy: what to know


Like many treatments that reduce estrogen activity, relugolix can cause hypoestrogenic side effects (symptoms related to lower estrogen).


The meta-analysis reports common adverse events such as:

  • Hot flushes(noted as frequent and dose-dependent)
  • Headache
  • Fatigue
  • Musculoskeletal pain
  • Nasopharyngitis


The paper also highlights the role of combination (“add-back”) therapy—relugolix used with estradiol and norethisterone acetate—which is designed to help mitigate hypoestrogenic side effects while maintaining benefit.


Important note: The article indicates that add-back therapy helps with tolerability and management of hypoestrogenic effects, but the blog data provided here does not include specific numerical results for every side-effect rate or discontinuation rate by regimen—so we can’t quantify exactly how much add-back reduces each side effect from this summary alone.


Relugolix combination therapy vs relugolix alone: is one better?


In subgroup analyses:

  • Combination therapy showed a numerically larger improvement (MD 8.86) than
  • Monotherapy (MD 4.99)

However, the authors report the difference between subgroups was not statistically significant. In other words, combination therapy may look better in numbers, but this meta-analysis could not confirm it is definitively better for pain outcomes based on the available trial data.


Is relugolix effective long term?


This is one of the biggest unanswered questions. The review notes that:

  • Benefits were most clearly demonstrated around 24 weeks
  • For longer follow-up periods (including 52 and 104 weeks), the confidence intervals crossed zero, meaning the meta-analysis could not conclusively demonstrate continued significant benefit at those extended durations


What this means for you: If you and your clinician are considering relugolix beyond 6 months, it’s reasonable to ask about:

  • symptom monitoring plans,
  • side effect management (including add-back therapy),
  • and what is known (and not known) about longer-term outcomes.


Actionable takeaways: questions to bring to your next appointment


If you’re considering relugolix for endometriosis-associated pain, these discussion points can help:


1. Am I a good candidate for an oral GnRH antagonist?

Ask how relugolix fits with your symptoms, prior treatments, and preferences.


2. Should I use relugolix alone or relugolix combination (add-back) therapy?

This review suggests add-back is important for managing hypoestrogenic effects; the pain benefit difference vs monotherapy wasn’t statistically definitive.


3. What side effects should I watch for, and how will we manage them?

Hot flushes, headache, fatigue, and muscle aches were commonly reported; hot flushes were dose-dependent.


4. What’s the plan for follow-up at 24 weeks—and beyond?

Long-term benefit past 24 weeks was not clearly established in this meta-analysis, so having a reassessment timeline matters.


Cautions and gaps: avoiding common misunderstandings


Based on the authors’ discussion, it’s worth keeping these points in mind:

  • Don’t assume long-term benefit is guaranteed. Evidence beyond ~24 weeks is limited/inconclusive in this analysis.
  • Don’t assume relugolix is “better than” leuprorelin. It appears comparable overall (non-inferior), but not clearly superior.
  • Don’t minimize side effects. Many are tied to lower estrogen, and the paper highlights the importance of add-back therapy for tolerability.
  • Results can vary between people and studies. The meta-analysis reported substantial heterogeneity (I² reported as 90.7%), suggesting responses may differ depending on regimen, comparator, and other study factors.

References

  1. Xie J, Ni X, Huang Q, Guo Y. Relugolix’s impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes. Frontiers in Endocrinology. 2025. (Systematic review and meta-analysis of RCTs; PRISMA-guided.) DOI: 10.3389/fendo.2025.1650579

Quick Answers

When is hysterectomy recommended for adenomyosis?

A hysterectomy is typically considered for adenomyosis when symptoms are severe and clearly uterus-driven—most often heavy bleeding (sometimes with anemia), intense cramping, pelvic pressure, and daily quality-of-life disruption—and you’re not planning future pregnancy. It’s the most definitive option because adenomyosis lives within the uterine muscle, so removing the uterus removes the source of the problem.


In practice, we usually weigh hysterectomy most strongly when conservative options haven’t brought acceptable relief, aren’t tolerated, or don’t fit your goals. The decision also depends on the pattern and extent of disease (diffuse adenomyosis versus a more focal adenomyoma that may be removable while preserving the uterus) and whether endometriosis may also be present. If endometriosis is part of the picture, it’s important to know that hysterectomy alone doesn’t treat disease outside the uterus—durable symptom relief depends on addressing all pain generators.


If you’re wondering whether you’re at the point where hysterectomy makes sense, our team can help clarify what’s most likely driving your symptoms, review imaging, and walk you through uterus-preserving versus definitive surgical paths so you can choose the option that best matches your relief and fertility priorities.

Read full answer

Why does ovarian cyst pain keep coming back?

Ovarian cyst pain can feel “recurrent” for a few different reasons. Some cysts are functional (they form with ovulation and then resolve), so the pain returns in a similar spot month after month even though it’s not the exact same cyst. In other cases, the cyst itself can come back or persist—especially if it’s an endometrioma (an ovarian cyst caused by endometriosis), which can behave differently than a simple cyst and may be associated with deeper pelvic disease.


Another common reason is that the cyst isn’t the whole story: endometriosis on the pelvic sidewall, uterosacral ligaments, bowel, bladder, or around the ovary can irritate the same nerves and tissues and make it feel like “my cyst is back” when the driver is actually inflammatory disease nearby. Adhesions (scar-like bands) can also tether the ovary and cause recurring pulling or sharp pain, even when imaging doesn’t show a large cyst. If your pain cycles, escalates, returns quickly after a “normal” ultrasound, or keeps recurring despite prior treatment, our team can help you map the pattern, interpret imaging with an endometriosis lens, and decide whether targeted evaluation and—when appropriate—excision surgery is the next best step.

Read full answer

Why do I have chronic fatigue and pelvic pain?

Chronic fatigue plus pelvic pain often feels “unexplainable” because it’s rarely caused by just one issue—and many of the most common drivers don’t show up on routine labs or a quick ultrasound. Endometriosis and adenomyosis can cause persistent pelvic pain, painful periods, bowel/bladder symptoms, and deep fatigue through inflammation, disrupted sleep, heavy bleeding (and possible iron deficiency), and the sheer energy cost of living with ongoing pain. It’s also common for more than one gynecologic condition to coexist—like fibroids, polyps, or benign cysts—so a single label may not fully match what you’re experiencing.


Another reason symptoms can persist is that the nervous system can become more pain-sensitive over time (often called central sensitization), meaning pain can spread, linger outside your cycle, or feel disproportionate to what imaging shows. In those cases, symptom relief alone can miss the bigger picture: we think in terms of both treating disease (for example, addressing endometriosis lesions or uterine drivers like adenomyosis/fibroids) and building a personalized pain-management plan so your body can “turn down the volume” on pain signals.


If your fatigue and pelvic pain have been brushed off or left without a clear plan, our team can help you sort through the likely contributors, including endometriosis/adenomyosis and common coexisting conditions, and map next steps that fit your goals. You can explore our educational resources on fatigue, chronic pelvic pain, and comprehensive treatment approaches, and reach out to schedule a consultation when you’re ready.

Read full answer

Why is my period pain so severe it disrupts my daily life?

Severe, life-disrupting period pain isn’t “normal cramps,” and it often points to an underlying driver that deserves a real explanation—not just symptom masking. One common cause is endometriosis, where tissue similar to the uterine lining grows outside the uterus and can irritate pelvic structures, trigger inflammatory chemicals, and sometimes involve organs like the bowel or bladder. Another key point is that pain severity doesn’t reliably match “stage,” so someone can have intense pain even if imaging looks normal or disease appears limited.


When period pain is severe, worsening over time, starts years after your first period, or comes with heavy bleeding, painful sex, bowel pain with periods, urinary pain, or fatigue, we think in patterns—because endometriosis and related conditions can overlap with pelvic floor dysfunction, nerve pain/central sensitization, GI dysbiosis, vascular issues, or adenomyosis. Our approach is to take your full timeline and flare pattern seriously and then tailor evaluation with careful exam and expertly interpreted imaging when helpful. If your pain is disrupting school, work, relationships, or daily functioning, reach out to schedule a consultation—our team can help you identify what’s driving it and map out a plan aimed at lasting relief.

Read full answer

Is uterine artery embolization (UAE) right for adenomyosis?

Uterine artery embolization (UAE)—sometimes called adenomyosis embolization—can be a good fit when your main goal is symptom relief while preserving the uterus, especially if heavy bleeding and uterine “bulk” symptoms are a big part of your day-to-day. It’s a radiology procedure that reduces blood flow to targeted uterine tissue with the aim of shrinking or calming adenomyosis-related changes. Many patients do report meaningful improvement in quality of life after UAE, and the recovery is typically shorter than major surgery.


Whether it’s “right” depends on what you’re trying to solve (bleeding, pain, fertility, or all three) and whether adenomyosis is the primary driver of your symptoms—or if endometriosis is also part of the picture. In head-to-head research in people with MRI-confirmed, therapy-resistant adenomyosis who were eligible for hysterectomy and not trying to conceive, both UAE and hysterectomy improved quality of life at 1 year, but hysterectomy tended to have an advantage for pain relief and satisfaction. If you want the most definitive option for uterus-driven symptoms, hysterectomy is the clearest “source removal” treatment, while UAE is better viewed as a uterus-preserving option that may help substantially but isn’t guaranteed to be as durable.


If you’re weighing UAE, our team can help you clarify your diagnosis (including whether endometriosis may be contributing), review your imaging and goals, and map out a plan that matches the level of relief you need—now and long-term. Explore our adenomyosis care resources, and reach out to schedule a consultation if you want a personalized decision pathway.

Read full answer

Reach Out

Have a question?

Lotus Endometriosis Institute provides California-based surgical evaluation and advanced excision care for patients with suspected endometriosis, adenomyosis, complex pelvic pain, and related conditions.


Many patients contact us from outside California to learn whether traveling for in-person evaluation and possible surgery may be appropriate.

Call Us

(424) 255-1340

(805) 920-0909

Fax: (805) 935-4338

Santa Monica, CA

2121 Santa Monica Blvd, Santa Monica, CA 90404

Operating Hours

8am - 5pm
Monday - Friday

Arroyo Grande, CA

154 Traffic Way, Arroyo Grande, CA 93420